31062331|t|Mammalian Target of Rapamycin at the Crossroad Between Alzheimer's Disease and Diabetes.
31062331|a|Accumulating evidence suggests that Alzheimer's disease may manifest as a metabolic disorder with pathology and/or dysfunction in numerous tissues. Adults with Alzheimer's disease suffer with significantly more comorbidities than demographically matched Medicare beneficiaries (Zhao et al, BMC Health Serv Res 8:108, 2008b). Reciprocally, comorbid health conditions increase the risk of developing Alzheimer's disease (Haaksma et al, PLoS One 12(5):e0177044, 2017). Type 2 diabetes mellitus is especially notable as the disease shares many overlapping pathologies observed in patients with Alzheimer's disease, including hyperglycemia, hyperinsulinemia, insulin resistance, glucose intolerance, dyslipidemia, inflammation, and cognitive dysfunction, as described in Chap. 8 of this book (Yoshitake et al, Neurology 45(6):1161-1168, 1995; Leibson et al, Am J Epidemiol 145(4):301-308, 1997; Ott et al, Neurology 53(9):1937-1942, 1999; Voisin et al, Rev Med Interne 24(Suppl 3):288s-291s, 2003; Janson et al. Diabetes 53(2):474-481, 2004; Ristow M, J Mol Med (Berl) 82(8):510-529, 2004; Whitmer et al, BMJ 330(7504):1360, 2005, Curr Alzheimer Res 4(2):103-109, 2007; Ohara et al, Neurology 77(12):1126-1134, 2011). Although nondiabetic older adults also experience age-related cognitive decline, diabetes is uniquely associated with a twofold increased risk of Alzheimer's disease, as described in Chap. 2 of this book (Yoshitake et al, Neurology 45(6):1161-1168, 1995; Leibson et al, Am J Epidemiol 145(4):301-308, 1997; Ott et al. Neurology 53(9):1937-1942, 1999; Ohara et al, Neurology 77(12):1126-1134, 2011). Good glycemic control has been shown to improve cognitive status (Cukierman-et al, Diabetes Care 32(2):221-226, 2009), and the use of insulin sensitizers is correlated with a lower rate of cognitive decline in older adults (Morris JK, Burns JM, Curr Neurol Neurosci Rep 12(5):520-527, 2012). At the molecular level, the mechanistic/mammalian target of rapamycin (mTOR) plays a key role in maintaining energy homeostasis. Nutrient availability and cellular stress information, both extracellular and intracellular, are integrated and transduced through mTOR signaling pathways. Aberrant regulation of mTOR occurs in the brains of patients with Alzheimer's disease and in numerous tissues of individuals with type 2 diabetes (Mannaa et al, J Mol Med (Berl) 91(10):1167-1175, 2013). Moreover, modulating mTOR activity with a pharmacological inhibitor, rapamycin, provides wide-ranging health benefits, including healthy life span extension in numerous model organisms (Vellai et al, Nature 426(6967):620, 2003; Jia et al, Development 131(16):3897-3906, 2004; Kapahi et al, Curr Biol 14(10):885-890, 2004; Kaeberlein et al, Science 310(5751):1193-1196, 2005; Powers et al, Genes Dev 20(2):174-184, 2006; Harrison et al, Nature 460(7253):392-395, 2009; Selman et al, Science 326(5949):140-144, 2009; Sharp ZD, Strong R, J Gerontol A Biol Sci Med Sci 65(6):580-589, 2010), which underscores its importance to overall organismal health and longevity. In this chapter, we discuss the physiological role of mTOR signaling and the consequences of mTOR dysregulation in the brain and peripheral tissues, with emphasis on its relevance to the development of Alzheimer's disease and link to type 2 diabetes.
31062331	0	29	Mammalian Target of Rapamycin	Gene	2475
31062331	55	74	Alzheimer's Disease	Disease	MESH:D000544
31062331	79	87	Diabetes	Disease	MESH:D003920
31062331	125	144	Alzheimer's disease	Disease	MESH:D000544
31062331	163	181	metabolic disorder	Disease	MESH:D008659
31062331	249	268	Alzheimer's disease	Disease	MESH:D000544
31062331	487	506	Alzheimer's disease	Disease	MESH:D000544
31062331	555	579	Type 2 diabetes mellitus	Disease	MESH:D003924
31062331	665	673	patients	Species	9606
31062331	679	698	Alzheimer's disease	Disease	MESH:D000544
31062331	710	723	hyperglycemia	Disease	MESH:D006943
31062331	725	741	hyperinsulinemia	Disease	MESH:D006946
31062331	743	761	insulin resistance	Disease	MESH:D007333
31062331	763	782	glucose intolerance	Disease	MESH:D018149
31062331	784	796	dyslipidemia	Disease	MESH:D050171
31062331	798	810	inflammation	Disease	MESH:D007249
31062331	816	837	cognitive dysfunction	Disease	MESH:D003072
31062331	1096	1104	Diabetes	Disease	MESH:D003920
31062331	1220	1229	Alzheimer	Disease	MESH:D000544
31062331	1364	1381	cognitive decline	Disease	MESH:D003072
31062331	1383	1391	diabetes	Disease	MESH:D003920
31062331	1448	1467	Alzheimer's disease	Disease	MESH:D000544
31062331	1784	1792	Diabetes	Disease	MESH:D003920
31062331	1835	1842	insulin	Gene	3630
31062331	1890	1907	cognitive decline	Disease	MESH:D003072
31062331	2033	2062	mammalian target of rapamycin	Gene	2475
31062331	2064	2068	mTOR	Gene	2475
31062331	2253	2257	mTOR	Gene	2475
31062331	2301	2305	mTOR	Gene	2475
31062331	2330	2338	patients	Species	9606
31062331	2344	2363	Alzheimer's disease	Disease	MESH:D000544
31062331	2408	2423	type 2 diabetes	Disease	MESH:D003924
31062331	2502	2506	mTOR	Gene	2475
31062331	2550	2559	rapamycin	Chemical	MESH:D020123
31062331	3199	3203	mTOR	Gene	2475
31062331	3238	3242	mTOR	Gene	2475
31062331	3347	3366	Alzheimer's disease	Disease	MESH:D000544
31062331	3379	3394	type 2 diabetes	Disease	MESH:D003924
31062331	Association	MESH:D020123	MESH:D000544
31062331	Association	MESH:D003920	2475
31062331	Association	MESH:D020123	3630
31062331	Association	MESH:D000544	2475

